The 8th China International Import ExpoDuring the China International Import Expo (hereinafter referred to as the "CIIE"), SanofiThe opening ceremony of the China International Import Expo (CIIE) and the global debut ceremony of cardiovascular innovations were officially held. Sanofi brought two innovative drugs in the cardiovascular field to the expo.—The global debut of Avketate tablets and Pleuselan sodium injection.

　　Oxana Monge, General Manager of Sanofi

　　"Plesulan sodium injection is the world's first siRNA drug targeting the innovative APOC3 mRNA, bringing new hope for the treatment of patients with familial chylomicronemia syndrome and severe hypertriglyceridemia.""We hope that these two innovative products can leverage the CIIE as an innovation accelerator and its powerful spillover effect to quickly transform from exhibits into commodities, benefiting Chinese patients more rapidly," said Oxana Monge.

　　Hypertrophic cardiomyopathy (HCM), the most common inherited heart disease, can lead to fatal risks such as sudden death, heart failure, and thromboembolism. It is one of the most common causes of sudden cardiac death in adolescents and athletes. Furthermore, approximately 43.5% of HCM patients progress to heart failure with preserved ejection fraction, and about 20% develop atrial fibrillation, which is the most common cause of thromboembolism in HCM patients.

　　It is noteworthy that approximately two-thirds of all hypertrophic cardiomyopathy patients have obstructive hypertrophic cardiomyopathy, which has a worse prognosis. For these patients, elevated left ventricular outflow tract pressure gradient (LVOT-G) is a key factor in disease progression, further exacerbating cardiac dysfunction and resulting in a mortality rate that is twice that of patients with non-obstructive hypertrophic cardiomyopathy (nHCM).

　　Dr. Dong Jianzeng, a standing committee member of the Chinese Society of Cardiology and the group leader of the Myopathy Group, and chief physician of the Department of Cardiovascular and Myopathy at Beijing Anzhen Hospital affiliated with Capital Medical University, stated that the focus of hypertrophic cardiomyopathy treatment has shifted from simply symptom relief to rapidly achieving multiple important treatment goals, such as rapidly reducing LVOTTAGE, which helps alleviate left ventricular outflow tract obstruction and thus reduces the risk of sudden cardiac death. However, most patients often find themselves in a dilemma during treatment because traditional drug therapy can only relieve some symptoms and cannot address the underlying causes of the disease, nor can it slow disease progression. Invasive treatments, on the other hand, require high levels of expertise and experience, have poor accessibility, and are generally associated with surgical complications and a high risk of re-intervention, resulting in low patient acceptance. Over time, this not only significantly impacts patients' prognosis and quality of life but also imposes a heavy disease and economic burden.

　　Furthermore, familial chylomicronemia syndrome and severe hypertriglyceridemia impose a heavy disease burden on patients due to their difficult-to-control and potentially life-threatening nature, especially severe hypertriglyceridemia, which affects nearly 20 million people in China. High triglycerides easily lead to complications, the most serious of which is acute pancreatitis. The mortality rate associated with severe acute pancreatitis attacks can reach 30%. Approximately 32% of pancreatitis patients experience recurrent attacks, potentially leading to repeated hospitalizations for abdominal pain, restrictions on daily diet, and severely impacting long-term health and quality of life.

　　Li Yong, Vice Chairman of the Chinese Cardiovascular Metabolism Alliance and Chief Physician of Internal Medicine (Cardiovascular Disease) at Huashan Hospital Affiliated to Fudan University, stated that currently there are no effective drugs specifically for familial chylomicronemia syndrome globally, and existing therapies offer limited improvement in severe hypertriglyceridemia. Some first-line drugs only reduce triglyceride levels by 20%-50% in individuals with high triglycerides, proving largely ineffective for patients with familial chylomicronemia syndrome. Furthermore, patients must rely on a strict low-fat, low-sugar diet and consistent high-intensity exercise weekly to control triglyceride levels, leading to difficulties in long-term adherence, unstable effects, and frequent unexplained spikes in triglycerides. The innovative drug prasigm sodium injection, making its global debut at the China International Import Expo, holds promise for breaking the "no controllable drug" dilemma of familial chylomicronemia syndrome in China.

　　Preslan sodium injection is the world's first siRNA drug that targets the innovative APOC3 mRNA.

　　Oxana Monge stated that Sanofi has been deeply involved in the cardiovascular field in China for nearly 30 years, bringing a wide range of innovative treatment options to Chinese patients through diverse innovation models. Many of these treatments have become the gold standard for meeting critical needs. Based on our profound experience in the cardiovascular field and our close collaborations with partners across various healthcare industries, we are continuously accelerating our innovation efforts to improve patient accessibility.

https://finance.eastmoney.com/a/202511073558179225.html